{"url_path":"/sec/bcax/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/0001628280-26-037377-index.html","accession_number":"0001628280-26-037377","cik":"0002023658","ticker":"BCAX","issuer_name":"Bicara Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2023658/0001628280-26-037377-index.html","primary_entity_key":"0002023658","primary_entity_name":"Bicara Therapeutics Inc."},"word_count":89,"has_tables":true,"body_markdown":"Item 9.01 - Financial Statements and Exhibits\n\n(d) The following exhibits are being filed herewith:\n\nExhibit No.\n\nDescription\n\n[99.1](asco2026_pressreleasexdraf.htm)\n\n[Press Release, dated May 21, 2026.](asco2026_pressreleasexdraf.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nBicara Therapeutics Inc.\n\nDate: May 21, 2026\n\nBy:\n\n/s/ Claire Mazumdar\n\nName:\n\nClaire Mazumdar, Ph.D.\n\nTitle:\n\nChief Executive Officer"}